Clinical Research Directory
Browse clinical research sites, groups, and studies.
Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents
Sponsor: Boston Medical Center
Summary
This study aims to improve retention in buprenorphine treatment, a medication used for opioid use disorder, through the use of a smartphone-delivered recovery support intervention. The intervention involves an Embodied Conversational Agent (ECA), a virtual, animated computer agent designed to simulate natural face-to-face conversations. ECAs have been shown to help individuals manage their healthcare in other settings, and this study seeks to evaluate their potential in supporting patients on medication for opioid use disorder (MOUD).
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-10-30
Completion Date
2026-12
Last Updated
2025-11-03
Healthy Volunteers
No
Conditions
Interventions
Embodied conversational agent (ECA)
The app with the ECA will be provided.
Technical support
Technical support will include assistance downloading and setting up the app on the participant's phone, walking them through a brief demonstration, and answering any questions the participant has about how to use the app.
Additional ECA messages
Weekly text messages will be provided reminding participants to use the app on behalf of OBAT clinical staff.
Additional incentives
Additional incentives will be provided after logging into the app for 20 days followed by monthly lotteries for those who log in 15 days per month
Locations (1)
Office-Based Addiction Treatment (OBAT) Clinic, BMC
Boston, Massachusetts, United States